The mechanistic target of rapamycin (mTOR) pathway plays a crucial role in cellular functions such as growth, proliferation, and survival. In the context of canine longevity, this pathway helps determine how a dog's body responds to nutrients, stress, and various environmental factors. When mTOR is overly activated, it can lead to accelerated aging and age-related diseases, which are common in older dogs. Conversely, inhibiting this pathway has been associated with increased lifespan in various organisms, including studies in mice that suggest potential benefits for dogs as well. Understanding the mTOR pathway is particularly relevant for dog owners who want to support their pets' health as they age. By targeting this pathway through dietary interventions or investigational compounds, researchers are exploring ways to promote healthier aging and reduce the risk of chronic diseases in dogs. This could mean a longer, more active life for your furry companion, enabling them to enjoy their golden years with vitality and joy.
GLOSSARY
mTOR pathway
The mTOR pathway is a cellular signaling pathway that regulates growth, metabolism, and aging in dogs and other organisms.
Why it matters
For dog owners, knowledge of the mTOR pathway may provide insights into how certain dietary choices and emerging therapies could help enhance their dog's quality of life as they age.
Tell us your dog's breed for personalized news
About one note per month, on average.
Keep exploring
countryPill watch: New ZealandbreedFrench Spaniel longevity briefglossaryGlossary: Time-restricted feedingblogWhy insurance preauthorization for the pill will be the next battlegroundglossaryGlossary: Geriatric screeningnewsPre-launch dossier: what we know about the canine longevity pill in 2026countryPill watch: Czech RepublicblogOwner-reported outcomes vs vet-reported outcomes: who do you believe?newsGeroscience consortium adds three more breeds to dose-finding studybreedGreat Pyrenees longevity briefglossaryGlossary: Reactive oxygen speciesblogWhat we learned from the first Australian rollout pilot